Results 171 to 180 of about 4,091 (198)

siRNAs targeting ANGPTL3 for mixed dyslipidemia

Med
The PROLONG-ANG3 trial demonstrated that two doses of solbinsiran, an siRNA targeting hepatic ANGPTL3, given 90 days apart, decreased concentrations of apoB, triglycerides, LDL-C, non-HDL-C, ANGPTL3, and hepatic fat content at day 180 in adults with mixed dyslipidemia.1 Long-term studies assessing the safety of solbinsiran and its efficacy in ...
openaire   +2 more sources

[Angptl3(angiopoietin-like 3)].

Nihon rinsho. Japanese journal of clinical medicine, 2004
Angiopoietin-like 3(Angptl3)-deficiency results in abnormally low lipid levels in mice. Angptl3-deficient mice showed enhanced very low density lipoprotein(VLDL) clearance compared with wild-type mice. Recombinant human ANGPTL3 protein inhibited lipoprotein lipase(LPL) activity in vitro, suggesting that Angptl3 affects VLDL triglyceride clearance by ...
Tetsuya, Shimizugawa, Yosuke, Ando, Mitsuru, Ono   +2 more
openaire   +1 more source

Abstract Or121: Functional dissection of ANGPTL3

Arteriosclerosis, Thrombosis, and Vascular Biology
Dyslipidemia is a risk factor for metabolic diseases, emphasizing the importance of regulating lipoprotein metabolism. Levels of lipoproteins are regulated, in part, by extracellular lipases including lipoprotein lipase (LPL) and endothelial lipase (EL).
Sydney Walker, Kelli Sylvers, Alex Dou, Shwetha Shetty, Brandon Davies   +4 more
openaire   +1 more source

Oligonucleotides targeting ANGPTL3

International Journal of Cardiology, 2018
Fei, Luo, Yuan, Guo, Xiangping, Li, Xinqun, Hu, Zhenfei, Fang   +4 more
openaire   +2 more sources

Is ANGPTL3 the next PCSK9?

Nature Reviews Endocrinology, 2017
Kiran Musunuru, Sekar Kathiresan
openaire   +1 more source

ANGPTL3 inhibition for hypercholesterolaemia

Nature Reviews Cardiology, 2020
openaire   +2 more sources

Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia

Journal of Clinical Medicine, 2023
Bozena Sosnowska, Stanisław Surma
exaly  

ANGPTL3 targeting: The power of versatile lipid-lowering

Atherosclerosis, 2018
Ariane R. Pessentheiner, Bastian Ramms, Philip L.S.M. Gordts   +2 more
openaire   +2 more sources

Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing ofAngptl3

Proceedings of the National Academy of Sciences of the United States of America, 2021
Min Qiu, Jinjin Chen, Mary Haas
exaly  

Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3

Circulation, 2018
Alexandra C Chadwick, Niklaus H Evitt, Kiran Musunuru   +2 more
exaly